12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Enzalutamide: Completed Phase III enrollment

Medivation and Astellas completed enrollment of 1,680 patients in the double-blind, placebo-controlled, international Phase III PREVAIL trial comparing once-daily 160 mg oral enzalutamide plus standard of care (SOC) vs. SOC alone. Last month, Medivation submitted an NDA to FDA...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >